Compare · BIIB vs FENC
BIIB vs FENC
Side-by-side comparison of Biogen Inc. (BIIB) and Fennec Pharmaceuticals Inc. (FENC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and FENC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $30.41B, about 83.0x FENC ($366.3M).
- Over the past year, BIIB is up 67.9% and FENC is up 24.9% - BIIB leads by 43.0 points.
- BIIB has been more active in the news (14 items in the past 4 weeks vs 6 for FENC).
- BIIB has more recent analyst coverage (25 ratings vs 5 for FENC).
- Company
- Biogen Inc.
- Fennec Pharmaceuticals Inc.
- Price
- $206.02-1.49%
- $10.51+0.33%
- Market cap
- $30.41B
- $366.3M
- 1M return
- +5.35%
- +17.05%
- 1Y return
- +67.92%
- +24.91%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 14
- 6
- Recent ratings
- 25
- 5
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Latest FENC
- Former Director Raykov Rosty sold $99,926 worth of shares (9,599 units at $10.41) as part of a pre-agreed trading plan, was granted 2,778 shares and exercised 15,597 shares at a strike of $2.45, increasing direct ownership by 7% to 138,855 units (SEC Form 4)
- Chief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.80% to 21,183 units (SEC Form 4)
- Chief Medical Officer Sayad Pierre Sargis was granted 168 shares, increasing direct ownership by 0.80% to 21,183 units (SEC Form 4)
- Chief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 63,984 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.59% to 290,972 units (SEC Form 4)
- Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.65% to 24,332 units (SEC Form 4)
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- SEC Form S-8 filed by Fennec Pharmaceuticals Inc.
- SEC Form 4 filed by Director Brughera Marco Maria
- SEC Form 4 filed by Director Cook Jodi A